CAPA – Page 404 – Pharma.Tips

Visual inspection rejects post-sterile filtration – patient safety risk analysis

Analyzing Visual Inspection Rejections Post-Sterile Filtration: A Structured Approach Visual inspection is a crucial process in pharmaceutical manufacturing, especially for injectable products. When product batches are rejected due to visual…

Endotoxin OOS during PAI readiness – FDA/MHRA inspection outcome

Investigation of Endotoxin OOS in PAI Readiness for Successful FDA/MHRA Outcomes In the fast-paced world of pharmaceutical manufacturing, ensuring the sterility and safety of injectable products is paramount. A common…

Visual inspection rejects during stability testing – FDA/MHRA inspection outcome

Understanding Visual Inspection Rejects During Stability Testing: An In-Depth Investigation Visual inspection rejects during stability testing can signal significant issues within a pharmaceutical manufacturing process. These rejects not only impact…

pH drift detected during stability testing – FDA/MHRA inspection outcome

Investigation of pH Drift Detected During Stability Testing: Implications for Compliance and Quality In the pharmaceutical manufacturing environment, maintaining established product specifications is paramount to ensuring product quality and compliance…

Dissolution failure during inspection prep – manufacturing vs material root cause

Dissolution Failures During Inspection Preparation: An In-Depth Investigation Dissolution failure during inspection preparation is a critical issue that can significantly impact the manufacturing process and product compliance. This article aims…

Capsule leakage complaint during bulk storage – CAPA inadequacy explained

Addressing Capsule Leakage Complaints during Bulk Storage: A Comprehensive Investigation Approach Capsule manufacturing defects, specifically relating to leakage during bulk storage, can have serious implications for product quality, regulatory compliance,…

Dissolution failure after supplier change – CAPA inadequacy explained

Dissolution Failure Following Supplier Change: Understanding CAPA Inadequacy Manufacturers often face quality issues, including dissolution failures, especially after changing suppliers. Such scenarios can trigger significant deviations and out-of-specification (OOS) results…

Capsule leakage complaint during inspection prep – regulatory inspection finding risk

Investigation of Capsule Leakage Complaints During Inspection Preparation Capsule leakage is a defect that can pose a significant risk during regulatory inspections. Identifying and resolving such defects promptly is critical…

Capsule fill weight variability during encapsulation – CAPA inadequacy explained

Understanding and Investigating Capsule Fill Weight Variability During Encapsulation In pharmaceutical manufacturing, the encapsulation process is a critical step, especially when it comes to dosage uniformity. Variability in capsule fill…

Content uniformity OOS during encapsulation – manufacturing vs material root cause

Investigating Out-of-Specification Content Uniformity during Capsule Encapsulation Out-of-Specification (OOS) reports regarding content uniformity during encapsulation can pose significant challenges in the pharmaceutical manufacturing sector. A single OOS event can lead…

Dissolution failure during bulk storage – CAPA inadequacy explained

Dissolution Failures During Bulk Storage: Investigating CAPA Inadequacies Dissolution failures during bulk storage pose significant risks, not only to product quality but also to compliance with stringent regulatory standards. These…

Dissolution failure after supplier change – manufacturing vs material root cause

Dissolution Failure After Supplier Change: Investigating Manufacturing and Material Root Causes The pharmaceutical sector often faces significant challenges when a supplier change leads to unexpected manufacturing defects, such as dissolution…